With the development of the structural and mechanistic knowledge of the Keap1-Nrf2 system, various Keap1-Nrf2 PPI inhibitors have been developed as potential therapeutics against chronic and inflammatory conditions, including pulmonary inflammation [32], cardiomyopathy [33] and myocarditis [34]. This evidence concerns the gene KEAP1 and myocarditis.